Search
Home
Latest
News
North America
Europe
Asia
Middle East
Global
Fortune 500
Fortune 500 U.S.
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Great Place To Work
Analytics
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
Home
Latest
Latest
News
North America
Europe
Asia
Middle East
Global
Fortune 500
Fortune 500
Fortune 500 U.S.
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Finance
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Great Place To Work
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
home
home
Wegovy
Wegovy
Page 5 of 6
Health
Weaning off Ozempic slowly instead of quitting abruptly can help prevent patients from regaining weight, study says
By
Ashleigh Furlong
and
Bloomberg
May 12, 2024
Retail
Denmark’s Novo Nordisk forecasts 27% sales surge but faces price pressure amid Eli Lilly competition
By
Naomi Kresge
and
Bloomberg
May 2, 2024
Retail
Novo Nordisk’s market value of $570 billion is now bigger than the entire Danish economy—creating a ‘Nokia risk’ for Denmark
By
Sanne Wass
,
Naomi Kresge
and
Bloomberg
May 1, 2024
Health
No evidence Ozempic and Wegovy raise risk of self harm, EU regulators said
By
Jonel Aleccia
and
The Associated Press
April 13, 2024
Health
Study shows Wegovy eases heart-failure symptoms for patients with diabetes—helpful to Novo as it argues insurers should pay for it
By
Naomi Kresge
and
Bloomberg
April 6, 2024
Health
Ozempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5
By
Madison Muller
,
Robert Langreth
and
Bloomberg
March 28, 2024
Retail
Wegovy and Ozempic have ignited a gold rush in pharma as well as an upsurge in fake ‘skinny jabs’, leading to surge in hospitalizations
By
Ashleigh Furlong
and
Bloomberg
March 13, 2024
Lifestyle
Novo Nordisk eclipses Tesla on positive trial results for a weight loss drug that may be more powerful than its own Wegovy
By
Prarthana Prakash
March 8, 2024
Health
62-year-old who lost 40 pounds in 9 months on Wegovy wants to stop the treadmill: ‘At some point you have to come off of them. I don’t want to be on them forever’
By
Jonel Aleccia
and
The Associated Press
March 7, 2024
Retail
Novo Nordisk’s Wegovy and Ozempic boom saved Denmark’s GDP from a no-growth 2023—and will help double its expected growth this year, country’s largest bank says
By
Niclas Rolander
and
Bloomberg
March 5, 2024
Retail
Novo Nordisk’s CEO says he’s fielding calls from ‘scared’ junk food suppliers asking for advice over Ozempic surge
By
Ryan Hogg
February 8, 2024
Retail
Novo Nordisk CEO says he was ‘surprised’ to see the popularity of weight-loss drugs in Europe—and people’s readiness to pay out of pocket for them
By
Prarthana Prakash
February 5, 2024
Retail
Novo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
By
Ryan Hogg
January 31, 2024
Health
North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
By
Simone Foxman
,
Madison Muller
and
Bloomberg
January 27, 2024
Health
Ozempic, Wegovy demand so strong Europe’s most valuable listed company plans ‘mega manufacturing facility’
By
Ellie Harmsworth
and
Bloomberg
December 24, 2023
Most Popular
Success
At 18, doctors gave him three hours to live. He played video games from his hospital bed—and now, he’s built a $10...
By
Preston Fore
Investing
Baby boomers have now 'gobbled up' nearly one-third of America's wealth share, and they're leaving Gen Z and...
By
Sasha Rogelberg
Success
Palantir cofounder calls elite college undergrads a ‘loser generation’ as data reveals rise in students seeking support...
By
Preston Fore